NASDAQ
10.04.26 | 21:59
72,59 US-Dollar
+0,46 % +0,33
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | Tarsus doses first patient in Lyme disease prevention trial | 2 | Investing.com | ||
| 31.03. | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | 249 | GlobeNewswire (Europe) | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| 25.03. | Tarsus Pharmaceuticals: Mizuho hebt Kursziel nach Zulassung in China an | 5 | Investing.com Deutsch | ||
| 25.03. | Mizuho raises Tarsus Pharmaceuticals stock price target on China approval | 2 | Investing.com | ||
| 23.03. | William Blair reiterates Outperform on Tarsus Pharmaceuticals stock | 1 | Investing.com | ||
| 23.03. | William Blair bestätigt "Outperform" für Tarsus: Blockbuster-Potenzial für Xdemvy | 1 | Investing.com Deutsch | ||
| TARSUS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 23.03. | Tarsus Pharmaceuticals, Inc: TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus | 224 | GlobeNewswire (Europe) | IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory... ► Artikel lesen | |
| 11.03. | Tarsus Pharmaceuticals auf der Barclays-Konferenz: Strategisches Wachstum und Herausforderungen | 2 | Investing.com Deutsch | ||
| 24.02. | Tarsus expects $670M-$700M 2026 sales as XDEMVY eyes blockbuster $2B+ potential while pipeline advances | 2 | Seeking Alpha | ||
| 24.02. | Tarsus Pharma's XDEMVY Sales Soar 150% In FY25, Peak Sales Potential To Exceed $2Bln | 5 | RTTNews | ||
| 23.02. | Earnings Call Transkript: Tarsus Pharmaceuticals verzeichnet starkes Wachstum in Q4 2025 | 1 | Investing.com Deutsch | ||
| 23.02. | Tarsus Pharmaceuticals, Inc. GAAP EPS of -$0.20 misses by $0.07, revenue of $151.6M beats by $7.04M | 1 | Seeking Alpha | ||
| 23.02. | Tarsus Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 23.02. | Tarsus Pharmaceuticals, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 23.02. | Tarsus vor Bewährungsprobe: Anleger blicken auf Umsatzdynamik und Profitabilität | 1 | Investing.com Deutsch | ||
| 18.02. | Former Allergan CEO David Pyott joins Tarsus Pharmaceuticals board | 4 | Investing.com | ||
| 18.02. | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors | 431 | GlobeNewswire (Europe) | IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical... ► Artikel lesen | |
| 18.02. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.02. | Tarsus Pharmaceuticals, Inc: Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026 | 1 | GlobeNewswire (USA) | ||
| 12.01. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,530 | +0,09 % | EQS-News: Evotec SE: Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden
07.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| MODERNA | 43,330 | -0,30 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| AMGEN | 299,00 | -0,10 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| NOVAVAX | 6,860 | -1,01 % | Activist investor revives campaign to overhaul Novavax board | ||
| REGENERON PHARMACEUTICALS | 631,90 | -1,06 % | Piper Sandler reiterates Overweight rating on Regeneron stock at $875 | ||
| VIKING THERAPEUTICS | 28,950 | -0,86 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| KUROS BIOSCIENCES | 26,460 | +0,38 % | Kuros schreibt 2025 schwarze Zahlen | Schlieren - Das Biotechunternehmen Kuros hat Wort gehalten und den Umsatz 2025 um mehr als 70 Prozent gesteigert. Getragen wurde die Entwicklung erneut durch das Knochenersatzprodukt MagnetOs. Konkret... ► Artikel lesen | |
| ABIVAX | 106,40 | -0,75 % | EQS-News: ABIVAX: Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
01.04.2026 / 22:05 CET/CEST
The... ► Artikel lesen | |
| MINDMAZE THERAPEUTICS | 0,310 | -8,55 % | Edison Group: Edison Issues Report on MindMaze Therapeutics (MMTX) | London, United Kingdom--(Newsfile Corp. - April 7, 2026) - Edison issues report on MindMaze Therapeutics (SIX: MMTX).MindMaze Therapeutics is a commercial-stage health technology company pioneering... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 3,140 | -0,48 % | Jefferies reiterates Iovance Biotherapeutics stock rating at buy | ||
| DENALI THERAPEUTICS | 16,305 | -0,55 % | Takeda tears up Denali partnership, returning dementia asset amid restructuring | ||
| CYTOMX THERAPEUTICS | 3,586 | -4,32 % | CYTOMX THERAPEUTICS INC zeigt klare Stärke | ||
| ROCKET PHARMACEUTICALS | 2,980 | 0,00 % | Aktien New York: Weitere Verluste - Iran-Krieg und China-News belasten | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Talfahrt fortgesetzt. Der anhaltende Iran-Krieg und die weiter steigenden Ölpreise mahnen die Anleger zur Vorsicht. Auf die Stimmung drückte... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,154 | 0,00 % | Voyager Therapeutics, Inc.: Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies... ► Artikel lesen |
TARSUS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,46 % bei einem Aktienkurs von 72,59 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TARSUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.